Evidence map›Paper›PMID 36672829›Full record

ReviewGenes2022

Jelena Trajković, Vedrana Makevic, Milica Pesic, Sofija Pavković-Lučić, Sara Milojevic, Smiljana Cvjetkovic, Randi Hagerman, Dejan B Budimirovic, Dragana Protic

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. International journal of molecular sciences · 2025
    Review
  2. Review
  3. Decoding Nucleotide Repeat Expansion Diseases: Novel Insights fromInternational journal of molecular sciences · 2024
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jelena TrajkovićFaculty of Biology, University of Belgrade, 11000 Belgrade, Serbia.
Vedrana MakevicDepartment of Pathophysiology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Milica PesicInstitute of Human Genetics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Sofija Pavković-LučićFaculty of Biology, University of Belgrade, 11000 Belgrade, Serbia.
Sara MilojevicDepartment of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Smiljana CvjetkovicDepartment of Humanities, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Randi HagermanMedical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, 2825 50th Street, Sacramento, CA 95817, USA.ORCID 0000-0001-5029-8448
Dejan B BudimirovicDepartment of Psychiatry, Fragile X Clinic, Kennedy Krieger Institute, Baltimore, MD 21205, USA.ORCID 0000-0001-7263-5134
Dragana ProticDepartment of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-2137-5405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fragile X syndrome (FXS) is a global neurodevelopmental disorder caused by the expansion of CGG trinucleotide repeats (≥200) in the Fragile X Messenger Ribonucleoprotein 1 (

Indexed as

Autism Spectrum DisorderDrosophila ProteinsFragile X SyndromeAnimalsAtaxiaDrosophila melanogasterFragile X Messenger Ribonucleoprotein 1TremorDrosophila ProteinsFMR1 protein, DrosophilaFragile X Messenger Ribonucleoprotein 1Drosophila melanogasterFMR1 geneFMRPFragile X syndromeFXTAS

Identifiers

PMID36672829
PMCPMC9859539

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.